Pharmaceutical Executive: How is federal policy reshaping life sciences investments? John Stanford: Federal policy is ...

The recommendation for Enflonsia is indicated for respiratory syncytial virus prevention in infants under eight months of age, expanding protection options ahead of the 2025–2026 season.